Extracellular vesicle therapeutics for liver disease

David A. Borrelli, Kiera Yankson, Neha Shukla, George Vilanilam, Taylor Ticer, Joy Wolfram

Research output: Contribution to journalReview article

15 Citations (Scopus)

Abstract

Extracellular vesicles (EVs) are endogenous nanoparticles that play important roles in intercellular communication. Unmodified and engineered EVs can be utilized for therapeutic purposes. For instance, mesenchymal stem cell (MSC)-derived EVs have shown promise for tissue repair, while drug-loaded EVs have the potential to be used for cancer treatment. The liver is an ideal target for EV therapy due to the intrinsic regenerative capacity of hepatic tissue and the tropism of systemically injected nanovesicles for this organ. This review will give an overview of the potential of EV therapeutics in liver disease. Specifically, the mechanisms by which MSC-EVs induce liver repair will be covered. Moreover, the use of drug-loaded EVs for the treatment of hepatocellular carcinoma will also be discussed. Although there are several challenges associated with the clinical translation of EVs, these biological nanoparticles represent a promising new therapeutic modality for liver disease.

Original languageEnglish (US)
Pages (from-to)86-98
Number of pages13
JournalJournal of Controlled Release
Volume273
DOIs
StatePublished - Mar 10 2018

Fingerprint

Liver Diseases
Therapeutics
Mesenchymal Stromal Cells
Nanoparticles
Liver
Extracellular Vesicles
Tropism
Pharmaceutical Preparations
Hepatocellular Carcinoma
Neoplasms

Keywords

  • Exosome
  • Extracellular vesicle
  • Liver
  • Mesenchymal stem cell
  • Nanovesicle

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Extracellular vesicle therapeutics for liver disease. / Borrelli, David A.; Yankson, Kiera; Shukla, Neha; Vilanilam, George; Ticer, Taylor; Wolfram, Joy.

In: Journal of Controlled Release, Vol. 273, 10.03.2018, p. 86-98.

Research output: Contribution to journalReview article

Borrelli, DA, Yankson, K, Shukla, N, Vilanilam, G, Ticer, T & Wolfram, J 2018, 'Extracellular vesicle therapeutics for liver disease', Journal of Controlled Release, vol. 273, pp. 86-98. https://doi.org/10.1016/j.jconrel.2018.01.022
Borrelli, David A. ; Yankson, Kiera ; Shukla, Neha ; Vilanilam, George ; Ticer, Taylor ; Wolfram, Joy. / Extracellular vesicle therapeutics for liver disease. In: Journal of Controlled Release. 2018 ; Vol. 273. pp. 86-98.
@article{fa4ef5da306c446d9c41028ce9065105,
title = "Extracellular vesicle therapeutics for liver disease",
abstract = "Extracellular vesicles (EVs) are endogenous nanoparticles that play important roles in intercellular communication. Unmodified and engineered EVs can be utilized for therapeutic purposes. For instance, mesenchymal stem cell (MSC)-derived EVs have shown promise for tissue repair, while drug-loaded EVs have the potential to be used for cancer treatment. The liver is an ideal target for EV therapy due to the intrinsic regenerative capacity of hepatic tissue and the tropism of systemically injected nanovesicles for this organ. This review will give an overview of the potential of EV therapeutics in liver disease. Specifically, the mechanisms by which MSC-EVs induce liver repair will be covered. Moreover, the use of drug-loaded EVs for the treatment of hepatocellular carcinoma will also be discussed. Although there are several challenges associated with the clinical translation of EVs, these biological nanoparticles represent a promising new therapeutic modality for liver disease.",
keywords = "Exosome, Extracellular vesicle, Liver, Mesenchymal stem cell, Nanovesicle",
author = "Borrelli, {David A.} and Kiera Yankson and Neha Shukla and George Vilanilam and Taylor Ticer and Joy Wolfram",
year = "2018",
month = "3",
day = "10",
doi = "10.1016/j.jconrel.2018.01.022",
language = "English (US)",
volume = "273",
pages = "86--98",
journal = "Journal of Controlled Release",
issn = "0168-3659",
publisher = "Elsevier",

}

TY - JOUR

T1 - Extracellular vesicle therapeutics for liver disease

AU - Borrelli, David A.

AU - Yankson, Kiera

AU - Shukla, Neha

AU - Vilanilam, George

AU - Ticer, Taylor

AU - Wolfram, Joy

PY - 2018/3/10

Y1 - 2018/3/10

N2 - Extracellular vesicles (EVs) are endogenous nanoparticles that play important roles in intercellular communication. Unmodified and engineered EVs can be utilized for therapeutic purposes. For instance, mesenchymal stem cell (MSC)-derived EVs have shown promise for tissue repair, while drug-loaded EVs have the potential to be used for cancer treatment. The liver is an ideal target for EV therapy due to the intrinsic regenerative capacity of hepatic tissue and the tropism of systemically injected nanovesicles for this organ. This review will give an overview of the potential of EV therapeutics in liver disease. Specifically, the mechanisms by which MSC-EVs induce liver repair will be covered. Moreover, the use of drug-loaded EVs for the treatment of hepatocellular carcinoma will also be discussed. Although there are several challenges associated with the clinical translation of EVs, these biological nanoparticles represent a promising new therapeutic modality for liver disease.

AB - Extracellular vesicles (EVs) are endogenous nanoparticles that play important roles in intercellular communication. Unmodified and engineered EVs can be utilized for therapeutic purposes. For instance, mesenchymal stem cell (MSC)-derived EVs have shown promise for tissue repair, while drug-loaded EVs have the potential to be used for cancer treatment. The liver is an ideal target for EV therapy due to the intrinsic regenerative capacity of hepatic tissue and the tropism of systemically injected nanovesicles for this organ. This review will give an overview of the potential of EV therapeutics in liver disease. Specifically, the mechanisms by which MSC-EVs induce liver repair will be covered. Moreover, the use of drug-loaded EVs for the treatment of hepatocellular carcinoma will also be discussed. Although there are several challenges associated with the clinical translation of EVs, these biological nanoparticles represent a promising new therapeutic modality for liver disease.

KW - Exosome

KW - Extracellular vesicle

KW - Liver

KW - Mesenchymal stem cell

KW - Nanovesicle

UR - http://www.scopus.com/inward/record.url?scp=85041408998&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041408998&partnerID=8YFLogxK

U2 - 10.1016/j.jconrel.2018.01.022

DO - 10.1016/j.jconrel.2018.01.022

M3 - Review article

VL - 273

SP - 86

EP - 98

JO - Journal of Controlled Release

JF - Journal of Controlled Release

SN - 0168-3659

ER -